特立帕肽在老年性骨质疏松症中的研究进展
Advances in Teriparatide in Senile Osteoporosis
DOI: 10.12677/jcpm.2025.42174, PDF,    科研立项经费支持
作者: 张泽金：云南中医药大学第一临床医学院，云南 昆明；黄家峥：昆明医科大学附属延安医院骨科，云南 昆明；邯郸市第一医院骨科，河北 邯郸；常 腾, 黄永东, 肖甲宇, 甘学文, 熊 鹰*：昆明医科大学附属延安医院骨科，云南 昆明
关键词: 特立帕肽；老年性骨质疏松症；骨形成促进物；临床疗效；Teriparatide； Senile Osteoporosis； Bone Formation Promoter； Clinical Effects
摘要: 特立帕肽(Teriparatide)作为一种骨形成促进药物，近年来在老年性骨质疏松症的治疗中展现了显著的疗效。本文综述了特立帕肽在老年性骨质疏松症中的应用现状，包括其作用机制、临床效果、安全性及未来研究方向，旨在为老年性骨质疏松症的治疗提供参考。
Abstract: Teriparatide, as a bone formation promoting drug, has shown remarkable efficacy in the treatment of senile osteoporosis in recent years. This article summarizes the current application of Teriparatide in senile osteoporosis, including its mechanism of action, clinical effects, safety and future research direction, aiming to provide a reference for the treatment of senile osteoporosis.
文章引用：张泽金, 黄家峥, 常腾, 黄永东, 肖甲宇, 甘学文, 熊鹰. 特立帕肽在老年性骨质疏松症中的研究进展[J]. 临床个性化医学, 2025, 4(2): 273-278. https://doi.org/10.12677/jcpm.2025.42174

参考文献

[1] Bijlsma, A.Y., Meskers, C.G.M., Westendorp, R.G.J. and Maier, A.B. (2012) Chronology of Age-Related Disease Definitions: Osteoporosis and Sarcopenia. Ageing Research Reviews, 11, 320-324. [Google Scholar] [CrossRef] [PubMed]
[2] Seriolo, B., Paolino, S., Casabella, A., Botticella, G., Seriolo, C. and Molfetta, L. (2013) Osteoporosis in the Elderly. Aging Clinical and Experimental Research, 25, 27-29. [Google Scholar] [CrossRef] [PubMed]
[3] 陈蕃. 21世纪老龄问题研究[M]. 北京: 宇航出版社, 1993.
[4] 中华人民共和国国家统计局. 中国统计年鉴[M]. 北京: 中国统计出版社, 2022.
[5] Jiang, Y., Zhao, J.J., Mitlak, B.H., Wang, O., Genant, H.K. and Eriksen, E.F. (2003) Recombinant Human Parathyroid Hormone (1-34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure. Journal of Bone and Mineral Research, 18, 1932-1941. [Google Scholar] [CrossRef] [PubMed]
[6] 林华. 骨质疏松症骨微结构的病变与药物治疗[J]. 中华骨科杂志, 2022, 42(22): 1531-1538.
[7] Fan, Y., Hanai, J., Le, P.T., Bi, R., Maridas, D., DeMambro, V., et al. (2017) Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. Cell Metabolism, 25, 661-672. [Google Scholar] [CrossRef] [PubMed]
[8] Kim, S.W., Pajevic, P.D., Selig, M., Barry, K.J., Yang, J., Shin, C.S., et al. (2012) Intermittent Parathyroid Hormone Administration Converts Quiescent Lining Cells to Active Osteoblasts. Journal of Bone and Mineral Research, 27, 2075-2084. [Google Scholar] [CrossRef] [PubMed]
[9] Neer, R.M., Arnaud, C.D., Zanchetta, J.R., et al. (2001) Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. The New England Journal of Medicine, 344, 1434-1441.
[10] Lindsay, R., Scheele, W.H., Neer, R., Pohl, G., Adami, S., Mautalen, C., et al. (2004) Sustained Vertebral Fracture Risk Reduction after Withdrawal of Teriparatide in Postmenopausal Women with Osteoporosis. Archives of Internal Medicine, 164, 2024-2030. [Google Scholar] [CrossRef] [PubMed]
[11] Niimi, R., Kono, T., Nishihara, A., Hasegawa, M., Matsumine, A., Kono, T., et al. (2016) Usefulness of Daily Teriparatide Treatment in Elderly Patients over 80 Years of Age. Osteoporosis International, 27, 1869-1874. [Google Scholar] [CrossRef] [PubMed]
[12] Wen, M., Luo, D., Li, J., Lu, B., Ling, P., Liu, F., et al. (2024) Comparing Musculoskeletal and Connective Tissue Disorder Risks of Teriparatide and Abaloparatide in Osteoporosis: An Analysis Based on FDA Adverse Event Reporting System (FAERS). Expert Opinion on Drug Safety, 18, 1-10. [Google Scholar] [CrossRef] [PubMed]
[13] 中国康复技术转化与发展促进会骨质疏松性骨折加速康复专业委员会, 中华医学会骨质疏松和骨矿盐疾病委员会骨与关节学组, 中国医师协会骨科医师分会骨质疏松工作委员会. 特立帕肽治疗骨质疏松性骨折中国专家共识(2024版) [J]. 中华医学杂志, 2024, 104(17): 1456-1465.
[14] Gilsenan, A., Midkiff, K., Harris, D., Kellier-Steele, N., McSorley, D. and Andrews, E.B. (2020) Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. Journal of Bone and Mineral Research, 36, 244-251. [Google Scholar] [CrossRef] [PubMed]
[15] Abdulelah, A., Haddad, B., Al-Hajahjeh, A., Al-Qirem, L.M. and El-Amayreh, L. (2023) The Risk of Developing Osteosarcoma after Teriparatide Use: A Systematic Review. Orthopedic Research and Reviews, 15, 191-198. [Google Scholar] [CrossRef] [PubMed]
[16] Ramchand, S.K., David, N.L., Lee, H., Bruce, M., Bouxsein, M.L., Leder, B.Z., et al. (2020) Effects of Combination Denosumab and High-Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA-HD HR-pQCT Study. Journal of Bone and Mineral Research, 36, 41-51. [Google Scholar] [CrossRef] [PubMed]
[17] Chiba, K., Okazaki, N., Kurogi, A., Watanabe, T., Mori, A., Suzuki, N., et al. (2022) Randomized Controlled Trial of Daily Teriparatide, Weekly High-Dose Teriparatide, or Bisphosphonate in Patients with Postmenopausal Osteoporosis: The TERABIT Study. Bone, 160, Article 116416. [Google Scholar] [CrossRef] [PubMed]
[18] Miller, P.D., Lewiecki, E.M., Krohn, K. and Schwartz, E. (2021) Teriparatide: Label Changes and Identifying Patients for Long-Term Use. Cleveland Clinic Journal of Medicine, 88, 489-493. [Google Scholar] [CrossRef] [PubMed]
[19] Cosman, F., Eriksen, E.F., Recknor, C., Miller, P.D., Guañabens, N., Kasperk, C., et al. (2010) Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 26, 503-511. [Google Scholar] [CrossRef] [PubMed]
[20] Leder, B.Z., Tsai, J.N., Uihlein, A.V., Wallace, P.M., Lee, H., Neer, R.M., et al. (2015) Denosumab and Teriparatide Transitions in Postmenopausal Osteoporosis (the Data-Switch Study): Extension of a Randomised Controlled Trial. The Lancet, 386, 1147-1155. [Google Scholar] [CrossRef] [PubMed]
[21] Rittmaster, R.S. (2000) Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone Followed by Alendronate. Journal of Clinical Endocrinology & Metabolism, 85, 2129-2134. [Google Scholar] [CrossRef] [PubMed]
[22] Kurland, E.S., Heller, S.L., Diamond, B., McMahon, D.J., Cosman, F. and Bilezikian, J.P. (2004) The Importance of Bisphosphonate Therapy in Maintaining Bone Mass in Men after Therapy with Teriparatide [Human Parathyroid Hormone(1-34)]. Osteoporosis International, 15, 992-997. [Google Scholar] [CrossRef] [PubMed]